Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Perou

Showing results (321-330 of 447) with videos related to

Pageof 45
Sort By:
Nature Communications|November 16, 2019
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancerGiada Zurlo, Xijuan Liu, Mamoru Takada, et al.
Plos One|May 17, 2012
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylationMatthew D Wilkerson, Xiaoying Yin, Vonn Walter, et al.
Nature Communications|November 4, 2025
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapyKazuki Nozawa, Masataka Sawaki, Yukari Uemura, et al.
The Journal of Molecular Diagnostics : JMD|May 25, 2013
Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimensMatthew D Wilkerson, Jason M Schallheim, D Neil Hayes, et al.
JAMA Oncology|January 5, 2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA TrialsAranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, et al.
Cancer Research|April 20, 2022
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast CancerSwarnima Singh, Nigel Lee, Diego A Pedroza, et al.
NPJ Breast Cancer|March 6, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapyTomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, et al.
Cancer Cell|May 26, 2012
Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancerKeli Xu, Jerry Usary, Philaretos C Kousis, et al.
Nature Communications|January 3, 2026
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancersDiego A Pedroza, Xueying Yuan, Fengshuo Liu, et al.
Breast Cancer Research : BCR|April 22, 2006
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assayLaurent Perreard, Cheng Fan, John F Quackenbush, et al.
Pageof 45

Showing results (321-330 of 447) with videos related to

Sort By:
Pageof 45
Nature Communications|November 16, 2019
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancerGiada Zurlo, Xijuan Liu, Mamoru Takada, et al.
Plos One|May 17, 2012
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylationMatthew D Wilkerson, Xiaoying Yin, Vonn Walter, et al.
Nature Communications|November 4, 2025
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapyKazuki Nozawa, Masataka Sawaki, Yukari Uemura, et al.
The Journal of Molecular Diagnostics : JMD|May 25, 2013
Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimensMatthew D Wilkerson, Jason M Schallheim, D Neil Hayes, et al.
JAMA Oncology|January 5, 2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA TrialsAranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, et al.
Cancer Research|April 20, 2022
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast CancerSwarnima Singh, Nigel Lee, Diego A Pedroza, et al.
NPJ Breast Cancer|March 6, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapyTomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, et al.
Cancer Cell|May 26, 2012
Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancerKeli Xu, Jerry Usary, Philaretos C Kousis, et al.
Nature Communications|January 3, 2026
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancersDiego A Pedroza, Xueying Yuan, Fengshuo Liu, et al.
Breast Cancer Research : BCR|April 22, 2006
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assayLaurent Perreard, Cheng Fan, John F Quackenbush, et al.
Pageof 45